Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on Its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1

UF Sid Martin Bio graduate Oragenics, Inc., announced the initiation of a Good Laboratory Practice (GLP) toxicology study to evaluate the safety profile and immunogenicity of its NT-CoV2-1 vaccine. The study is designed to provide Investigational New Drug (IND)-enabling data to help advance to human clinical studies. Oragenics has contracted with Frontage Laboratories (through its wholly owned subsidiary Experimur) to conduct the study, with top-line interim data expected in August.

Glenn Washer, Frontage’s North American President and EVP of Global Safety & Toxicology commented, “We are delighted to support Oragenics on what could be the next generation of vaccines to combat COVID-19 infections. With the recent acquisition of Experimur, Frontage is well positioned to support Oragenics’ development needs through the IND and beyond.”

Learn more about Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on Its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1